
EC approves Biocon Biologics’ denosumab biosimilars Vevzuo and Evfraxy
The European Commission (EC) has approved Biocon Biologics’ biosimilars referencing Amgen’s bone disease therapy denosumab. Biocon Biologics’ Vevzuo has been authorised to prevent bone complications in adults with advanced cancer involving the bone, and to …